Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab

Archives of Dermatology

Volumn 142, Issue 5, 2006, Pages 555-558

  Weinberg, Jeffrey M ^a   Siegfried, Elaine C ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN; DIFLORASONE DIACETATE; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; GAMMA INTERFERON; MONTELUKAST; PETROLATUM; PIMECROLIMUS; PREDNISONE; PSEUDOMONIC ACID; TACROLIMUS;

ADULT; ALOPECIA AREATA; ANAMNESIS; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; MALE; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; SKIN BIOPSY; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT REFUSAL; ULTRAVIOLET B RADIATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; CHILD; DERMATITIS, ATOPIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEG; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 33646550540     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.5.555     Document Type: Article

References (8)

1. Saini R, Tutrone WD, Weinberg JM. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr Pharm Des. 2005;11:273-280.
2. Lebwohl M. Psoriasis. Lancet. 2003;361:1197-1204.
3. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
4. Leung DY, Jain N, Leo HL. New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol. 2003;15:634-638.
5. van Joost T, Kozel MM, Tank B, Troost R, Prens EP. Cyclosporine in atopic dermatitis: modulation in the expression of immunologic markers in lesional skin. J Am Acad Dermatol. 1992;27:922-928.
6. Raptiva (efalizumab) [package insert]. South San Francisco, Calif: Genentech, Inc; 2004.
7. Gordon KB, Papp KA, Hamilton TK, et al; Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073-3080.
8. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-38.